Molecular pathology.
Personalized.

Solid tumor

Blood cancer

Liquid biopsy

Custom assays

Genomic sequencing assays and analysis software

Because the global fight against cancer requires the best personalized molecular detection tools to get the right answer the first time

Sample-to-certainty targeted sequencing

NGS implementation goes far beyond sequencing. With trusted assay development capabilities, best in class molecular detection technology and purpose-built genomics analysis platform, we take you from a question to an answer you can be confident in.
Simply solving the most complex genomic problems

Archer library preparation assays are simple and work from low-input FFPE samples to provide
- Novel gene fusion detection
- Sensitive variant detection
- Robust CNV and expression information
Purpose-built analysis and integrated genomics platform
- Powerful analysis for unprecedented data quality
- Simple, intuitive user experience
- Workflow management and systems integration
- Flexible and secure local or cloud-based deployment
Scalable and flexible NGS implementation

Any of Archer’s custom or off-the-shelf assays are able to have new genes added to them without impacting assay performance. Adoption of Archer assays enables future growth based on new discoveries.
Companion diagnostic development

With the best detection technology, a global reach and ISO13485 design control, Archer is the preferred NGS CDx partner.

From sample-to-certainty

Assay Designer

Build a panel from scratch or supplement an existing assay

PreSeq^® QC

Pre-screen FFPE samples to determine DNA or RNA quality prior to library preparation

Archer^® assays

Generate libraries with Anchored Multiplex PCR (AMP™) enrichment chemistry

Sequencing

Efficiently sequence disease-targeted libraries created using Archer assays

Archer Analysis

Confidently detect fusions, CNVs, ITDs and other variants

Featured Videos

Detecting FLT3 ITDs with Archer blood cancer assays

Archer Immunoverse TCR and BCR sequencing kits

More videos...

Archer in the news

Feb

12

2019

Press release: ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

Jan

30

2019

Press release: ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company

Jan

8

2019

Press release: ArcherDX’s Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration

Oct

3

2018

Press release: Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration

Apr

12

2018

Press release: Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Mar

26

2018

Press release: ArcherDX and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services

Mar

20

2018

Press release: ArcherDX Closes $35 Million Series A Financing

More news...

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

Email

sales@archerdx.com
customer-support
@archerdx.com
tech@archerdx.com

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures.